Inhalt
Hauptmenü
Fußmenü
Home
About Us
Overview
Strategy
Management
Advising Founders
Team
Scientific Advisory Board
Pipeline
Overview
Clinical Trials
Disease Areas
Scientific Background
T Cells and Inflammation
Transcription Factors
DNAzymes
Publications
Scientific Collaborations
Intellectual Property
Media
Press Releases
Mailing List
Press Kits & Downloads
Picture Gallery
Contacts
Sitemap
Home
About Us
Overview
Strategy
Management
Advising Founders
Team
Scientific Advisory Board
Pipeline
Overview
Clinical Trials
Disease Areas
Scientific Background
T Cells and Inflammation
Transcription Factors
DNAzymes
Publications
Scientific Collaborations
Intellectual Property
Media
Press Releases
sterna biologicals commences phase I clinical trial of first-in-class DNAzyme-based GATA-3 antagonist for the treatment of moderate to severe Th2-driven asthma
Mailing List
Press Kits & Downloads
Picture Gallery
sterna biologicals commences phase I clinical trial of first-in-class DNAzyme-based GATA-3 antagonist for the treatment of moderate to severe Th2-driven asthma
Contacts
© sterna biologicals GmbH & Co. KG • Biomedizinisches Forschungszentrum (BMFZ) • Hans-Meerwein-Straße 2 • D-35043 Marburg
